
Autonomy in Practice: Trauma-Informed Pelvic Exams
'I just can't do it.'
My patient, a 43-year-old woman with a history of childhood sexual abuse and young adult assault, sat across from me, her shoulders hunched. She'd avoided pelvic exams for years, despite her desire for cervical cancer screening. Even scheduling an appointment triggered panic and dissociation. Years of therapy — including eye movement desensitization and reprocessing (EMDR) — had helped, but not enough. Previous providers, even those she trusted, had 'gotten the job done' while ignoring her pleas to slow down or stop. Sadly, her experience is all too common.
Why Trauma-Informed Exams Matter
To many clinicians, pelvic exams are routine. But for patients with a history of trauma — sexual, medical, or both — pelvic exams can feel terrifying and impossible. Even well-intentioned can fall short if they move too quickly or miss subtle cues. Traditional models prioritize efficiency and focus on 'getting it done,' often at the expense of patient comfort and agency.
And let's be honest: The legacy of medicine has not always inspired trust. For female patients, the impact of historic injustices like nonconsensual gynecologic procedures on enslaved women or the abuses of Dr Larry Nassar continue to reverberate — especially among marginalized communities. For many, mistrust of medical settings is not just personal, but generational.
What the Literature Offers (and What It Doesn't)
General guidance on trauma-informed care is plentiful but rarely offers concrete, actionable, step-by-step guidance on treating patients who have severe trauma responses with pelvic exams. Talli Rosenbaum's mindfulness-based pelvic floor physical therapy stands out as a specific protocol for working with clients with sexual pain.
As a sexual medicine specialist, I also wanted to develop a process rooted in patient autonomy, explicit consent, and nonexploitation — skills that benefit patients in medical settings as well as in their sexual relationships.
I designed my approach to:
Equip patients with self-advocacy tools. Teach patients their rights, such as requesting an exam under anesthesia or their right to stop a medical procedure at any time. Coach patients on how to use clear, assertive language to communicate their needs effectively to medical providers.
Teach patients their rights, such as requesting an exam under anesthesia or their right to stop a medical procedure at any time. Coach patients on how to use clear, assertive language to communicate their needs effectively to medical providers. Honor the body's wisdom. I've explored a variety of trauma-informed approaches, including Somatic Experiencing, Eugene Gendlin's Focusing, and Gina Ogden's 4-D Wheel, and these modalities sharpened my ability to notice subtle bodily signals. By recognizing these signals, providers can help their patients listen to the quiet voice of their body's discomfort before it escalates and needs to 'shout.'
I've explored a variety of trauma-informed approaches, including Somatic Experiencing, Eugene Gendlin's Focusing, and Gina Ogden's 4-D Wheel, and these modalities sharpened my ability to notice subtle bodily signals. By recognizing these signals, providers can help their patients listen to the quiet voice of their body's discomfort before it escalates and needs to 'shout.' Make space for internal conflicts. Internal Family Systems language helps patients acknowledge the parts of themselves that seek healing alongside those that deeply fear vulnerability.
My Protocol: Principles and Process
Three core principles shape my patient encounters:
No exam unless necessary for the patient's goals or questions. Proceed only if the exam aligns with your collaborative care plan and if the patient explicitly consents. The patient is in control of every step of the exam. Encourage self-advocacy and support and validate any request to slow down or pause the process at any point. No enduring is allowed. Although we cannot guarantee that a patient won't experience moments of discomfort, we can shift, adjust, or stop if anything feels mentally, emotionally, or physically uncomfortable. We do not want any patient 'white-knuckling it' through the exam.
Share these core principles with your patient before any exam. Then, describe the exam in detail and ask the patient if there are any components they'd like to adjust or exclude.
Stepwise, Patient-Led Approach
Assessment and window of tolerance. Start in a talking office — not the exam room — to establish the patient's 'window of tolerance,' which is the range in which patients can engage without shutting down or becoming overwhelmed. Ask the patient, 'How will I know you're uncomfortable?' and 'How does your body let you know when it's not okay?' During medical exams, individuals with a history of trauma can unknowingly push through their body's early warning system. To avoid escalation, together we identify early signs of discomfort (eg, elevated heart rate, shallow breathing, muscle tension, mental haze) and plan on grounding techniques (eg, breathing exercises, humming, orienting) we can implement if or when they arise. Gradual exposure. Proceed step by step. First describe the exam, then have the patient imagine the exam, then enter the exam room, and continue to advance in that fashion. Each session progresses only as far as the patient's window of tolerance allows. Cultivating interoception. Treat early warnings as vital information. If a patient notices and reports a sensation of discomfort, welcome it as an important indicator that something in the environment needs to shift. If a patient gets the 'shakes' after accomplishing a difficult step, reframe this reaction as a sign of resilience, as the body has completed a stress cycle. Celebrate every act of self-advocacy and rehearse how to communicate needs to future providers, reinforcing the notion that the patient is the expert on their lived experience. Environmental adjustments. Encourage patients to bring a support person, a warm blanket, music, or even a stuffed animal. Simple changes like covering anatomical diagrams or putting fun socks on the footrests can make a substantial difference.
What Success Looks Like
After 15 sessions, a 39-year-old with lifelong medical anxiety who experienced panic during her first pelvic exam at 21 years of age went from viewing her anxiety as insurmountable to tolerating a full pelvic exam with the support of her partner. Thanks to this trauma-informed approach, we were able to complete the pelvic exam and identify a manageable muscular issue.
Another patient, who'd experienced a psychogenic seizure during her first pelvic exam, completed a Pap smear by the seventh session. We discovered that her initial psychogenic seizure was probably due to a typical vasovagal response. As a result of our sessions, she now uses grounding tools with new providers — proudly advocating for herself in both medical and personal settings.
At the end of our sessions, my female patients often tearfully ask, 'Why isn't it always this way?'
Barriers and Realities
Let's not sugarcoat it: The doctor-patient power imbalance is real and demands our constant vigilance. Furthermore, systemic barriers such as limited time, inadequate space, and liability-driven policies often make trauma-informed approaches challenging to implement in routine care. Although not every provider may be able to fully adopt a practice like this, we can all work to move the field toward more patient-led, trauma-informed care. Ultimately, the goal is a future where trauma-informed exams are the norm, not the exception.
Takeaway for Clinicians
Clinicians should screen for past traumas of all types and recognize that routine medical care is inherently vulnerable and boundary crossing; as such, trauma responses will inevitably arise. We all need to be prepared with tools and attitudes that can help our patients move through them.
So, the next time you perform a pelvic exam:
Slow down.
Center consent and bodily autonomy.
Listen to bodily cues, not just spoken words.
Equip yourself with tools to help patients when trauma responses are activated.
Empower patients to lead the process.
Evaluate the necessity of your planned exams and always explain their rationale.
Collaborate with the patient to create an environment for exams that feels empowering and safe.
Let's move away from 'getting it done' and start 'getting it right.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Ionis doses first subject in Phase III trial of Angelman syndrome therapy
Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at treating individuals with Angelman syndrome (AS), a rare neurodevelopmental disorder. The placebo-controlled, double-blind trial will recruit nearly 200 AS adults and children with a maternal UBE3A gene deletion or mutation. Over a 52-week treatment period, subjects will be randomised in a 2:1 ratio and given either the therapy or a placebo. Quarterly doses of either 40mg or 80mg of ION582 will be administered to those in the active treatment groups. After the initial treatment phase, eligible subjects will have the opportunity to enter a long-term extension segment of the trial, where the therapy will be administered for up to two years. The primary goal of the trial is to assess improvements in expressive communication using the Bayley Scales for Infant and Toddler Development-4 (Bayley-4), a direct clinician-administered assessment tool. Expressive communication deficits are notably the most burdensome symptoms for caregivers of individuals with AS. The trial will also evaluate secondary endpoints, including overall disease severity, communication, cognition, motor functioning, sleep, and daily living skills, as well as other exploratory endpoints. ION582 has previously shown promise in the multiple ascending dose (MAD) portion of the Phase I/II open-label HALOS trial, demonstrating clinical improvement across various functional domains such as cognition, motor function, and communication. The RNA-targeted antisense medicine, ION582, works by inhibiting the expression of the UBE3A antisense transcript (UBE3A-ATS) to potentially increase the UBE3A protein production, to treat AS. Ionis Pharmaceuticals neurology senior vice-president Holly Kordasiewicz: 'This placebo-controlled study will evaluate ION582 in both children and adults with either UBE3A deletion or mutation and builds on earlier encouraging findings from our Phase I/II HALOS study. 'With ION582, we continue to advance our leading wholly owned neurology pipeline, which includes eight medicines in clinical development across a range of rare and more prevalent diseases.' Last year, Ionis announced the design for the Phase III trial of ION582 for the treatment of AS, following discussions with the US Food and Drug Administration. "Ionis doses first subject in Phase III trial of Angelman syndrome therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Yahoo
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Company Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025 Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention. Event DetailsDate: Tuesday, June 17, 2025Time: 3:15 p.m. ETLocation: Room 153A, Boston Convention & Exhibition Center The Company's lead asset, SkinJect Inc., is a development stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The Company is currently conducting a Phase 2 clinical study SKNJCT-003 in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The Company also announced expanding clinical trial sites in Europe. The Company also has a clinical design (SKNJCT-004) currently underway in United Arab Emirates (UAE). The study is expected to randomize 36 patients in four sites in UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. In April 2025, the Company announced entering into a binding letter of intent to acquire Antev Ltd. ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. For further information contact: Carolyn Bonner, President (610) 636-0184cbonner@ Anna Baran-Djokovic, SVP Investor Relations (305) 615-9162adjokovic@ About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE. In April 2025, the Company also announced entering into a binding letter of intent to acquire Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company's intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at and on SEDAR+ at Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
America might finally make childbirth free—and moms could be the biggest winners
'This is how much it costs to give birth in America: $44,318.41.' That was the now-viral TikTok from a mom just days postpartum, scrolling through the itemized bill at home. Her insurance only covered $20,353.62—despite paying $2,500 a month for coverage for her family of five. This mom's story isn't an outlier. According to the Peterson-KFF Health System Tracker, privately insured families in the U.S. pay an average of $3,000 out-of-pocket for childbirth on average—just for having a baby. By 'choosing' to have a baby with a midwife in a birth center, I personally had to pay a $10k fee upfront. (Wanting midwifery care in a calm setting for my super fast labors didn't feel like a choice, but in America, it is.) Moms bear so many burdens for having babies. And one devastating cost that sets so many families back financially when they're just beginning life together is the price of childbirth, even with insurance. We're talking million-dollar NICU bills. $50k c-section charges. A financial punishment for doing the most critical work in a country: bringing the next generation of citizens into the world. But that may soon change. A bipartisan group of senators has introduced a bill that could be a game-changer for millions of American families. The Supporting Healthy Moms and Babies Act (S.1834) was announced on May 21, 2025, and aims to eliminate all out-of-pocket costs related to prenatal care, childbirth, and postpartum services for those with private health insurance. The bill's sponsors—Sens. Cindy Hyde-Smith (R-MS), Tim Kaine (D-VA), Josh Hawley (R-MO), and Kirsten Gillibrand (D-NY)—say the legislation is about protecting families from being buried in medical debt at one of the most vulnerable times in life. 'Bringing a child into the world is costly enough without piling on cost-share fees that saddle many mothers and families with debt,' Sen. Hyde-Smith said in a statement announcing the legislation. 'By relieving financial stresses associated with pregnancy and childbirth, hopefully more families will be encouraged to embrace the beautiful gift and responsibility of parenthood.' A companion bill is expected in the House, led by Rep. Jared Golden (D-ME), who told Vox, 'This idea is simple and powerful: Pregnancy and childbirth are normal parts of family life. So, insurance companies should treat it like the routine care it is and cover the cost—not stick people with huge medical bills.' While the average out-of-pocket cost is around $3,000, the financial burden can be far worse for many: 17% of privately insured moms face bills over $5,000 1% are hit with bills exceeding $10,000 17.5% of women with private insurance report problems paying medical bills Nearly 9% say they couldn't pay them at all These numbers are not just statistics—they represent real parents delaying care, going into debt, or struggling to recover financially in the fragile weeks after childbirth. If passed, the bill would expand the list of 'essential health benefits' under the Affordable Care Act to include full-spectrum maternity care. Medicaid already covers these services in full, and that's how 41% of births in the U.S. are paid for. But for the 178 million people on private insurance plans? Birth is still a budget-buster. The new legislation would require private insurers to pick up the tab. That means: Prenatal care (including appointments and ultrasounds) Labor and delivery Hospital stays Postpartum recovery and mental health care Neonatal and perinatal services Lactation support The estimated premium hike to cover it all? About $30 per year, according to Lawson Mansell, policy analyst at the Niskanen Center, who conducted the cost modeling for the bill. Mansell told Vox this proposal is the simplest way, on an administrative level, to make birth free. Related: Too many U.S. moms are in debt from giving birth. They deserve better. Beyond the financial relief, this bill has the potential to improve health outcomes for moms and babies. Research backs this up: A report by the Washington State Office of the Insurance Commissioner found that eliminating cost-sharing for prenatal services is associated with improved maternal and infant outcomes, including fewer preterm births and higher birth weights. So in addition to relieving the stress families face, covering prenatal care fully makes it more likely that moms actually get it. Another study published in BMC Public Health linked removing financial barriers under the Affordable Care Act to increased use of preventive care, such as mammography and Pap tests. While the study focused on these services, the findings suggest that eliminating financial barriers can encourage timely and consistent healthcare utilization. The bill's sponsors come from across the political spectrum—and so do its supporters. Everyone from the American Medical Association and the American College of Obstetricians and Gynecologists to anti-abortion groups like Americans United for Life and Susan B. Anthony Pro-Life America have voiced support. Even Planned Parenthood Action Fund commented they 'generally supports legislation to make the cost of maternal health care and parenting more affordable.' Related: The cost of giving birth is getting more expensive—and some families are getting hit with childbirth debt If the bill becomes law, the financial landscape of pregnancy would change dramatically—especially for those in the 'missing middle': families who earn too much for Medicaid but not enough to easily afford thousands in delivery fees. It would also offer immediate relief for parents managing multiple financial burdens at once: high rent, unpaid leave, child care costs, student loans. You know, new motherhood. Call your representatives. Especially if you have private insurance and have ever been slammed with a delivery bill. You can find contact info at and Share your story. Lawmakers have said constituent birth bill stories played a big role in shaping this legislation. Talk about it on social. If your childbirth costs shocked you, say so. Use hashtags like #MakeBirthFree and tag your reps. This moment is historic not just because it's bipartisan, but because it signals a new kind of family policy thinking: one where moms aren't expected to 'figure it out' in isolation, one giant bill at a time. As Yuval Levin of the American Enterprise Institute put it in a policy brief, 'Substantively and symbolically, bringing the out-of-pocket health care costs of childbirth to zero is an ambitious but achievable starting point for the next generation of pro-family policies.' Whether you're pregnant now or years past it, you probably remember your hospital bill—and you definitely remember how it made you feel. Exhausted. Angry. Maybe even ashamed. This new bill says: No more. And moms deserve that. Sources: Family-Friendly Policies for the 119th Congress. February 2025. AEI. Family-Friendly Policies for the 119th Congress. America might finally make childbirth free. May 2025. Vox. America might finally make childbirth free. Americans United for Life Applauds Bipartisan Innovative Policy Proposal. May 2025. America United for Life. Americans United for Life Applauds Bipartisan Innovative Policy Proposal to Make Maternal Healthcare More Affordable. AMA advocacy to improve maternal health. May 2025. AMA. AMA advocacy to improve maternal health. Impact of removing cost sharing. 2019. BMC Public Health. Impact of removing cost sharing under the affordable care act (ACA) on mammography and pap test use. New bipartisan proposal would remove childbirth costs. May 2025. Niskanen Center. New bipartisan proposal would remove childbirth costs and confusion for parents. Characteristics of Mothers by Source of Payment for the Delivery. May 2023. CDC. Characteristics of Mothers by Source of Payment for the Delivery: United States, 2021. About the Affordable Care Act. Us Department of Health an Human Services. About the Affordable Care Act. Out-of-pocket medical bills childbirth. National Library of Medicine. Out-of-pocket medical bills from first childbirth and subsequent childbearing. The Association of Childbirth with Medical Debt. National Library of Medicine. The Association of Childbirth with Medical Debt in the USA, 2019–2020. Sentators introduce bill to ease financial burden of pregnancy. Cindy Hyde-Smith. SENATORS INTRODUCE BIPARTISAN BILL TO EASE THE FINANCIAL BURDEN OF PREGNANCY, CHILDBIRTH. Women who Give Birth Incur Nearly $19,000 in Additional Health Costs. KFF. Women who Give Birth Incur Nearly $19,000 in Additional Health Costs, Including $2,854 More that They Pay Out of Pocket.